bioRxiv · 10.1101/2024.11.25.625229
Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.
Abstract
We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for Clostridioides difficile infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functionally superior systemic antibodies and supported strong memory B cell and gut IgA responses. This pharmaceutically acceptable adjuvant platform holds promise for developing a next-generation CDI vaccine.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Naz, F., Hagspiel, N., Xu, F., Thompson, B., Moreau, G. B., Young, M., Herbein, J., Fox, C. B., Petri, W. A., Abhyankar, M. M.. 2024-11-26. Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.. https://doi.org/10.1101/2024.11.25.625229
Cite the original work for its findings. Save a collection to share your selection of sources.